IBT
RARE icon

International Biotechnology Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History

International Biotechnology Trust’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$8.91M Buy
250,052
+170,000
+212% +$6.74M 3% 11
2023
Q2 		$3.69M Sell
80,052
-184,000
-70% -$8.53M 1.12% 27
2023
Q1 		$10.6M Buy
264,052
+90,000
+52% +$3.86M 2.95% 8
2022
Q4 		$8.06M Hold
174,052
– – 2.49% 15
2022
Q3 		$7.2M Buy
174,052
+164,442
+1,711% +$8.45M 2.31% 15
2022
Q2 		$161K Sell
9,610
-223,490
-96% -$13.8M 1.68% 19
2022
Q1 		$2.07M Buy
233,100
+95,000
+69% +$6.61M 0.47% 43
2021
Q4 		$11.6M Buy
138,100
+35,000
+34% +$2.85M 2.59% 13
2021
Q3 		$9.29M Buy
103,100
+43,000
+72% +$3.89M 2.24% 14
2021
Q2 		$5.73M Buy
60,100
+40,000
+199% +$4.17M 1.51% 21
2021
Q1 		$2.29M Buy
+20,100
New +$2.74M 0.6% 31
2018
Q2 		– Sell
-41,000
Closed -$2.09M – 61
2018
Q1 		$2.09M Buy
+41,000
New +$2.06M 0.82% 30

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

International Biotechnology Trust's RARE Position: Q3 2023 in Review

International Biotechnology Trust increased its Ultragenyx Pharmaceutical (RARE) stake by 212% in Q3 2023, buying an estimated $6.74M and bringing the position to 250,052 shares worth $8.91M. The position accounts for 3% of the portfolio, ranked #11.

International Biotechnology Trust first reported a position in RARE in Q1 2018 and has held it in 12 quarters since. The position peaked at $11.6M in Q4 2021. 220 funds tracked by Wall St. Rank hold RARE as of Q3 2023.

  • International Biotechnology Trust held 250,052 shares of Ultragenyx Pharmaceutical worth $8.91M as of Q3 2023.
  • International Biotechnology Trust bought 170,000 Ultragenyx Pharmaceutical shares in Q3 2023, an estimated $6.74M.
  • Ultragenyx Pharmaceutical made up 3% of International Biotechnology Trust's portfolio in Q3 2023, its #11 holding.
  • International Biotechnology Trust first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and has held it in 12 quarters since.
  • International Biotechnology Trust's Ultragenyx Pharmaceutical position peaked at $11.6M in Q4 2021.
  • 220 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.